Treatment of <scp>HCV</scp> infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin

Abstract

Our data confirm excellent SVR outcomes and favourable safety and tolerability profiles with ledipasvir/sofosbuvir without ribavirin in post-liver transplant recipients infected with HCV, despite treatment guidelines to use ribavirin.